By turning a patient's own immune cells into stronger cancer-fighting cells, CAR T-cell therapy has transformed how some ...
A 2026 review finds that TCR-engineered T cells have entered early clinical testing for hepatocellular carcinoma, but safety, antigen heterogeneity and immune suppression remain major barriers.
Despite the major impact of GLP-1 receptor agonists on weight management, post-discontinuation rebound remains a significant ...
By turning a patient's own immune cells into stronger cancer-fighting cells, CAR T-cell therapy has transformed how some ...
Postdoctoral researcher Hannah Waterman at Duke University explores how communication between pancreatic alpha and beta cells ...
Alector (ALEC) holds steady despite trial failures, pivoting to ABC platform and Roche deal extending cash to 2029.
Biogen is rated Hold ahead of Q3 2026 earnings, with cautious optimism due to pipeline catalysts. Read more on BIIB stock ...
Cardiac fibrosis has long been viewed as one of the most stubborn problems in cardiovascular medicine, largely because the ...
HER3‑targeted PET imaging demonstrated tumor uptake and retention, supporting ATNM‑400's potential to deliver sustained alpha radiation to tumors over a timeframe consistent with Actinium‑225's 10-day ...
Alector (NASDAQ:ALEC) outlined its strategy to advance brain-penetrant therapies for neurodegenerative diseases, highlighting an anti-amyloid beta antibody for Alzheimer’s disease and two siRNA ...
KRAS- and ALK-driven lung cancer models, supporting mutation-agnostic development as monotherapy and in combination with established ...
The metabolic dysfunction-associated steatohepatitis competitive landscape report delivers important insights into approved as well as ongoing research on 200+ pipeline MASH drugs, clinical strategies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results